Moderna, Inc. (MRNA) shares surged 5.04% in the after-hours trading session on Tuesday, defying expectations after an analyst lowered its price target on the pharmaceutical company's stock.
The rally came after Redburn Atlantic cut its price target on MRNA to $55 from $73 while maintaining a neutral rating. Despite the downward revision, which suggests potentially weaker expectations for Moderna's future performance or valuation, investors seemed undeterred and pushed the stock higher.
Overall, analysts covering Moderna have an average rating of "hold" on the stock, with a mean price target of $53.35 according to data from FactSet. The divergence between Moderna's after-hours gain and the analyst's more cautious outlook highlights the differing views on the company's prospects.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。